Karl Hård

Karl Hård has extensive experience in investor relations and communications within the biotechnology and pharmaceutical sectors. Currently serving as Head of Investor Relations and Communication at Egetis Therapeutics AB since February 2022, Hård has held various senior roles, including Head of Investor Relations at Redx Pharma and Kiadis Pharma, as well as a consulting position at Optimum Strategic Communications. Prior to these roles, Hård spent nearly two decades at AstraZeneca, culminating in the position of VP Investor Relations. Hård's academic background includes a Ph.D. in Bio-organic Chemistry from Utrecht University and a Master’s Degree in Biochemistry from the University of Helsinki, along with roles in academia as an Assistant Professor and various research positions.